olaparib,abiraterone
astrazeneca,merck,janssen
['propel', 'prostate', 'brca']
updated results of propel in prostate cancer presented at #esmo2022. propel ph3 study show clearly benefit of abi + olap. mainly for brcam + pts (85/796 pts ~10%) 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"